MODIWAKE (Modafinil 200 mg) is a pharmaceutical-grade eugeroic compound formulated as oral tablets, indicated primarily for the clinical management of excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. Modafinil is a well-established wakefulness-promoting agent with an extensive clinical and neuropsychopharmacological research history, distinguished mechanistically from classical psychostimulant compounds.
 
✔ Key Research Insights
Studied for its eugeroic properties, promoting wakefulness in research subjects without the sympathomimetic activity profile associated with traditional stimulant compounds
Investigated for its clinical efficacy in reducing excessive daytime sleepiness in documented populations with narcolepsy, obstructive sleep apnea, and shift work sleep disorder
Researched for its modulatory effects on dopaminergic and noradrenergic neurotransmitter pathways, with the precise mechanism of action remaining an active subject of neuropsychopharmacological inquiry
Examined for its capacity to maintain wakefulness and alertness during designated working hours in shift work disorder subject populations, without substituting for adequate sleep in clinical observations
Documented for its tolerability profile, with commonly reported effects including headache, nausea, nervousness, and insomnia in clinical trial populations; serious adverse events such as severe dermatological reactions or psychiatric symptoms noted as rare occurrences in post-marketing surveillance literature
 
📦 Product Specifications
Product: MODIWAKE
Molecule: Modafinil
Concentration: 200 mg per tablet
Form: Oral tablet
Clinical reference: dosage should be determined by a qualified healthcare professional. Standard clinical protocols reference once-daily morning administration at 200 mg, with individualized adjustment based on indication and patient response.
 
⚙ How It Works
Modafinil is a eugeroic compound whose precise mechanism of central nervous system action has not been fully elucidated in pharmacological research. Current evidence from neuropsychopharmacological studies suggests that modafinil inhibits dopamine reuptake transporter activity in research subjects, resulting in elevated extracellular dopamine concentrations in brain regions associated with wakefulness regulation. Secondary effects on noradrenergic, histaminergic, orexinergic, and serotonergic systems have also been documented in mechanistic research, contributing to its wakefulness-promoting activity through a multi-neurotransmitter profile distinct from classical stimulant compounds such as amphetamines. Unlike traditional psychostimulants, modafinil does not produce pronounced sympathomimetic cardiovascular effects or significant dopamine surge in reward pathways at therapeutic doses, as documented in comparative neuroimaging and pharmacodynamic research. Clinical studies consistently emphasize that modafinil promotes wakefulness during designated periods of required alertness but does not compensate for cumulative sleep deficit or replace the physiological requirement for adequate sleep in treated subject populations.
 
⭐ Product Overview
Pharmaceutical-grade modafinil formulation with consistent potency and bioavailability per tablet
Established eugeroic compound with an extensive clinical research history in sleep disorder pharmacotherapy
Mechanistically distinct from classical stimulant compounds, as documented across neuropsychopharmacological and clinical literature
Indicated for the management of excessive daytime sleepiness across multiple documented sleep disorder diagnoses, as referenced in international neurology and sleep medicine guidelines
Widely recognized in clinical and regulatory literature under the modafinil and wakefulness-promoting agent designations worldwide